The Research, Scholarship, and Artistic Achievement Awards nomination deadline has been extended to May 31, 2024. Click here for more information.

miRNA Compositions and Methods for Treating Age-Related Macular Degeneration and Pathological Anigogenesis and Fibrosis in the Heart, Lung and Liver


Tulane University is actively seeking commercial entities to further develop and commercialize a miRNA drug which can treat multiple disease targets.


Useful for treatment of multiple factors of Age-related Macular Degeneration. These targets have implications in other disease states including pathological angiogenesis and fibrosis of the heart, lung, and liver.

Current Work

This biologic has been tested with in vitro assays as well as in an in vivo mouse model of Choroidal Neovascularisation (CNV).


Intellectual Property

Provisional US Application 62,822,503

Available For

Exclusive License in a Field
Non-exclusive License
Scientific Collaboration

For more information, please contact: